EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 瑞慈醫療服務控股有限公司 | | 股份代號 | 01526 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 宣派及派付末期股息及暫停辦理股份過戶登記手續 | | 公告日期 | 2026年3月26日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.02 HKD | | 股東批准日期 | 2026年6月17日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.02 HKD | | 匯率 | 1 HKD : ...

Financial Performance - For the year ending December 31, 2025, the revenue was RMB 2,795.6 million, a decrease of 4.4% compared to RMB 2,924.5 million for the year ending December 31, 2024[3]. - The gross profit for the year ending December 31, 2025, was RMB 1,207.3 million, an increase of 3.4% from RMB 1,167.8 million for the year ending December 31, 2024[3]. - The profit attributable to owners of the company for the year ending December 31, 2025, was RMB 307.1 million, compared to RMB 297.3 million for the year ending December 31, 2024[3]. - The adjusted EBITDA for the year ending December 31, 2025, was RMB 1,094.5 million, an increase of 3.8% from RMB 1,054.1 million for the year ending December 31, 2024[3]. - The net profit for the year was RMB 383.0 million, an increase from RMB 354.7 million in the previous year[6]. - The company reported a net profit attributable to shareholders of RMB 307,128,000 for 2025, up from RMB 297,321,000 in 2024, reflecting a growth of 3.0%[46]. - The company reported a net loss provision for financial assets of RMB 3,269,000, a decrease from RMB 8,248,000 in the previous year[27]. - The company’s income tax expense increased to RMB 184,311,000 in 2025 from RMB 129,266,000 in 2024, an increase of 42.7%[45]. Assets and Liabilities - The total assets as of December 31, 2025, were RMB 4,878.4 million, compared to RMB 4,858.5 million as of December 31, 2024[10]. - The total equity attributable to owners of the company was RMB 1,646.1 million as of December 31, 2025, compared to RMB 1,345.8 million as of December 31, 2024[10]. - As of December 31, 2025, the group's current liabilities exceeded its current assets by RMB 44,416,000[16]. - The total liabilities related to lease obligations decreased to RMB 1,376,508,000 in 2025 from RMB 1,503,278,000 in 2024, a reduction of 8.4%[12]. - The company has a bank loan of RMB 635,600,000 as of December 31, 2025, down from RMB 797,000,000 in 2024[37]. - Total borrowings decreased to RMB 635.6 million as of December 31, 2025, from RMB 797.0 million in 2024[86]. - Debt-to-equity ratio improved to 33.8% as of December 31, 2025, down from 46.4% in 2024[89]. Revenue Segmentation - For the year ended December 31, 2025, the total revenue was RMB 2,795,553,000, with the integrated hospital segment contributing RMB 441,326,000 and the health check center segment contributing RMB 2,386,267,000[24]. - The comprehensive hospital business generated revenue of RMB 441.3 million in 2025, down 27.6% from RMB 604.4 million in 2024, influenced by the expansion of major public hospitals in the region[63]. - The health check-up business revenue increased by 1.2% to RMB 2,386.3 million in 2025, compared to RMB 2,358.8 million in 2024, driven by growth in the premium service line under the "Xingyuanhui" brand[64]. Operational Metrics - The group provided 294,379 outpatient services during the reporting period, a decrease of 4.2% compared to the previous year, and 25,045 inpatient services, down 14.4%[55]. - The average occupancy rate of the nursing home within the group was 85.0%, an increase from 80.9% in 2024, with an average of 90 residents per day[55]. - The group operates 86 health check centers nationwide as of the end of 2025, up from 83 in 2024, with 79 centers already in operation[56]. Cost Management - The company's selling costs decreased by 9.6% to RMB 1,588.2 million in 2025, down from RMB 1,756.7 million in 2024, due to effective cost control measures[66]. - Administrative expenses fell to RMB 221.4 million in 2025 from RMB 265.1 million in 2024, attributed to ongoing cost reduction initiatives[69]. - The company’s employee benefits expenses decreased to RMB 1,017,085,000 in 2025 from RMB 1,091,246,000 in 2024, a decline of 6.8%[43]. Future Outlook - The company anticipates that the overall market size of China's healthcare services will reach RMB 10.5 trillion by 2025, driven by increasing demand for quality healthcare services[50]. - The company plans to enhance its comprehensive hospital services and aims to establish Nantong Ruici Hospital as a leading tertiary hospital in Nantong within the next 3 to 5 years[60]. - The company intends to leverage the "silver economy" by expanding its rehabilitation and elderly care services, including the completion and opening of the second phase of Ruici Meidi Nursing Home[60]. - The company anticipates that the health service industry will reach a total scale of RMB 16 trillion by 2030, presenting significant opportunities for private healthcare services[60]. Governance and Compliance - The audit committee reviewed the consolidated financial statements for the year ending December 31, 2025, including accounting principles and internal controls[109]. - The company has adopted the corporate governance code as per the listing rules to enhance management and protect shareholder interests[104]. - The board consists of four executive directors and three independent non-executive directors, ensuring a strong independent element[106]. - The company has maintained compliance with the public float requirements set by the Hong Kong Stock Exchange[103].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 RICI HEALTHCARE HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） 陳先生已確認無任何有關彼辭任之事宜須提請聯交所及本公司股東垂注。 董事會宣佈李杏韶女士（「李女士」）已獲委任為公司秘書及授權代表，自2026年 3月26日起生效。李女士現為丹諾商業服務有限公司上市服務部經理，負責為 上市公司提供公司秘書及合規服務。彼於公司秘書領域擁有逾10年經驗。彼為 香港公司治理公會及特許公司治理公會的會士，並獲授予特許秘書及公司治 理師雙重資格。 李女士於2019年取得香港都會大學（前稱香港公開大學）公司治理碩士學位。 – 1 – 董事會謹此感謝陳先生為本公司作出之寶貴貢獻。董事會謹此歡迎李女士加入。 董事會進一步宣佈自2026年3月26日起，本公司香港主要營業地點之地址將更 改為香港上環永樂街60-66號昌泰商業大廈5樓504室。 承董事會命 瑞慈醫療服務控股有限公司 （股份代號： ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 RICI HEALTHCARE HOLDINGS LIMITED 中國香港，2026年3月12日 （於開曼群島註冊成立的有限公司） 於本公告日期，董事會由四名執行董事，即方宜新醫師、梅紅醫師、方浩澤先生及林曉穎女 士；及三名獨立非執行董事，即姜培興先生、黃斯穎女士及田文果先生組成。 （股份代號：1526） 董事會會議召開日期 瑞慈醫療服務控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會 會議將於2026年3月26日（星期四）舉行，藉以（其中包括）考慮及批准本公司及 其附屬公司於截至2025年12月31日止年度之經審核全年業績公告及其發佈，以 及考慮建議派付末期股息（如有）。 承董事會命 瑞慈醫療服務控股有限公司 主席 方宜新 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 瑞慈醫療服務控股有限公司（本公司）（於開曼群島注冊成立的有限公司） 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01526 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 ...

Group 1 - The A-share PCB concept sector experienced a strong rally in the morning session, with International Composite Materials (301526) hitting the daily limit up of 20% [1] - Other companies such as Jin'an Guoji, Honghe Technology, Zhongcai Technology, China Jushi, and Shandong Fiberglass also reached the daily limit up, indicating a broad positive sentiment in the sector [1] - Stocks like Changhai Co. and Lite Optoelectronics saw significant gains, contributing to the overall upward trend in the PCB sector [1] Group 2 - The short drama game and film theater sectors faced a decline at the beginning of the trading session, with Hengdian Film and Jin Yi Film hitting the lower limit [5] - Following the initial drop, the lower limit was lifted, but companies like Xingfu Lanhai saw a decline of over 5%, while Baida Qiancheng and Huace Film experienced notable losses [5] - The overall performance of the short drama game and film theater sectors indicates a challenging market environment [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 RICI HEALTHCARE HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） （股份代號：1526） 補充公告 須予披露交易 收購該物業 進行收購事項的理由及裨益 董事認為，鑒於該物業所在地區徐匯區的物業市場情況以及上海及中國物業 市場的整體狀況，上海市商品房預售合同的條款（包括代價）屬公平合理。 於評估代價時，本公司已參考近期過去12個月內同類二手物業的市場單位價格 （介乎每平方米約人民幣200,000元至人民幣300,000元），以及賣方於同期及先 前階段在毗鄰地區發展的其他預售一手物業的近期成交價（自2025年9月起至該 公告日期止），其與代價具有可比性，且與代價一致。上述物業的建造工程已 告完成。本公司認為，代價與當前市價相若。在評估代價時，本公司亦已考慮 該物業本身的性質及質量。該物業為位處上海市中心徐匯區黃金地段的獨特 – 1 – 低密度開發項目，擁有豐富的綠化空間設計 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 瑞慈醫療服務控股有限公司（本公司）（於開曼群島注冊成立的有限公司） 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01526 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 ...

Core Insights - Shanghai Ruici Medical Investment Group and Shanghai Institute of Major Infectious Diseases and Biosecurity signed a strategic cooperation agreement to advance chronic disease health examination standards and collaborate in preventive medicine [1] Group 1: Strategic Cooperation - The agreement aims to establish scientific health examination standards and address potential health management needs [1] - Both parties will leverage their strengths in medical services and technological innovation to enhance public health services and cultivate medical research talent [1] Group 2: Organizational Background - The Shanghai Institute of Major Infectious Diseases and Biosecurity was approved by the Shanghai Municipal Government in July 2020 and officially established in November 2020 [2] - It operates as a public welfare research institution jointly built by the Shanghai Municipal Government and Fudan University, managed under a council-led system [2]

第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 瑞慈醫療服務控股有限公司（本公司）（於開曼群島注冊成立的有限公司） 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01526 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0. ...